Ishika Mahajan

Prof. Ishika Mahajan

Manipal Academy of Higher Education, Manipal, India
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Aruni GhoseAruni Ghose
Aruni Ghose
ABAnita Bolina
Anita Bolina
IMIshika Mahajan
Ishika Mahajan
SRSyed Ahmer Raza
Syed Ahmer Raza
MCMiranda Clarke
Miranda Clarke
Stergios BoussiosStergios Boussios
Stergios Boussios
Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely affordable and accessible screening strategy to reduce mortality from OC is still ongoing. This coupled with the late-stage presentation and poor prognosis harbours significant health-economic implications. OC is also the most heritable of all cancers, with an estimated 25% of cases having a hereditary predisposition. Advancements in technology have detected multiple mutations, with the majority affecting the BRCA1 and/or BRCA2 genes. Women with BRCA mutations are at a significantly increased lifetime risk of developing OC, often presenting with a high-grade serous pathology, which is associated with higher mortality due to its aggressive characteristic. Therefore, a targeted, cost-effective approach to prevention is paramount to improve clinical outcomes and mortality. Current guidelines offer multiple preventive strategies for individuals with hereditary OC (HOC), including genetic counselling to identify the high-risk women and risk-reducing interventions (RRI), such as surgical management or chemoprophylaxis through contraceptive medications. Evidence for sporadic OC is abundant as compared to the existing dearth in the hereditary subgroup. Hence, our review article narrates an overview of HOC and explores the RRI developed over the years. It attempts to compare the cost effectiveness of these strategies with women of the general population in order to answer the crucial question: what is the most prudent clinically and economically effective strategy for prevention amongst high-risk women?

Verified
Journal Article
Open access
PDF file
IMIshika Mahajan
Ishika Mahajan
Aruni GhoseAruni Ghose
Aruni Ghose
DGDeepika Gupta
Deepika Gupta
MMManasi Manasvi
Manasi Manasvi
SBSaisha Bhandari
Saisha Bhandari
Stergios BoussiosStergios Boussios
Stergios Boussios
COVID-19 has been responsible for widespread morbidity and mortality worldwide. Invasive mucormycosis has death rates scaling 80%. India, one of the countries hit worst by the pandemic, is also a hotbed with the highest death rates for mucormycosis. Cancer, a ubiquitously present menace, also contributes to higher case fatality rates. All three entities studied here are individual, massive healthcare threats. The danger of one disease predisposing to the other, the poor performance status of patients with all three diseases, the impact of therapeutics for one disease on the pathology and therapy of the others all warrant physicians having a better understanding of the interplay. This is imperative so as to effectively establish control over the individual patient and population health. It is important to understand the interactions to effectively manage all three entities together to reduce overall morbidity. In this review article, we search for an inter-relationship between the COVID-19 pandemic, emerging mucormycosis, and the global giant, cancer.

16 March 2023 in ecancermedicalscience
Verified
Journal Article
Open access
AVAnjana Vinod
Anjana Vinod
IMIshika Mahajan
Ishika Mahajan
AGAruni Ghose
Aruni Ghose
SSSaraswathy Sreeram
Saraswathy Sreeram
Primary neuroendocrine breast cancer—an unusual occurrence Anjana Vinod1, Ishika Mahajan1,2, Aruni Ghose3,4,5,6 and Saraswathy Sreeram7 1Department of M